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Metabolic syndrome (MS) is a growing public health concern characterized by interrelated metabolic risk factors including central obesity, hypertension, and impaired glucose and lipid homeostasis. MS is associated to atherosclerosis, fatty liver, type 2 diabetes and cancer (1). MS is characterized by a low-grade inflammatory state, with increased production of inflammatory mediators and abnormal function of immune cells (1). Although the detailed molecular mechanisms that link MS to metabolically triggered inflammation (termed “meta-inflammation”) remain elusive, it is now suggested that the abnormal activation of the host innate immune system might be orchestrated by an altered gut microflora (the associated impairment of gut barrier function might enable microorganisms to trigger inflammation (2)) and/or an dysfunctional adipose tissue (AT; when AT reaches its limit of expandability and function, adipokines and inflammatory cytokines are released) (3). An altered function of the inflammatory system is crucial for atherosclerotic plaque formation that results from the interaction between modified lipoproteins, monocyte-derived macrophages, T cells, and the normal cellular elements of the arterial wall (4). The study of the gene expression signature of circulating immune cells characterizing MS could thus provide new opportunity to understand the complicated network of the pathophysiological events linking MS, systemic inflammation and atherosclerosis, and could represent a powerful tool for accurately and non-invasively assess and stage MS and comorbities with the chance of identifying novel therapeutic targets.
Recent studies have proposed peripheral blood mononuclear cells (PBMCs) as a reliable model for studying cardiovascular biology system and as carrier of genomic biomarkers of the whole body inflammatory status in different conditions  ADDIN REFMGR.CITE (5-7). Hence, PBMC transcriptomic is a promising strategy for investigating whole-genome adaptive responses underling the complexity of the cardiovascular system in relation to inflammation (8). Nevertheless, the regulation of gene transcription is complex, controlled at several levels, and likely to involve post-transcriptional mechanisms which have been partially elucidated in recent years. MicroRNAs (miRNAs) are key regulators of gene expression and protein translation through binding to complementary target sites in the 3’-untranslated regions (3’UTRs) of target messenger RNA, resulting in decreased mRNA levels and/or reduced protein formation (9). Alterations in the levels of miRNAs affect gene expression and thereby cell function in several pathophysiological conditions, including inflammation, metabolism, and cardiovascular disease  ADDIN REFMGR.CITE (10-12).




Patient recruitment and clinical, biochemical and instrumental assessment of MS were collected at the Clinica Medica “Augusto Murri” (University Hospital of Bari, Italy). Thirty-three healthy subjects (17M:16F; mean age 31.5±6.4 yrs.), and 33 patients at the first diagnosis of MS (16M:17F; mean age 47.3±12.2 yrs.) were recruited for this study (baseline characteristics are shown in Table S1). The diagnosis of MS was made according to the presence of three or more criteria for MS according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults classification (Adult Treatment Panel III, ATP III) (16). 
None of the subjects included in the study underwent pharmacological therapy, except of anti-hypertensive drugs for MS patients. Baseline characteristics of subjects are provided in Table S1. Presence of MS complications (e.g. cardiovascular disease, CAD; cerebrovascular diseases) as well as of other disease (e.g. endocrine disorders, hepatic or renal disease, autoimmune disease, acute and chronic systemic syndromes) were exclusion criteria. Subjects with a daily consumption of alcohol over 25 g/day were also excluded. In all subjects, background information was collected, including lifestyle and medical history. All subjects underwent clinical examination. Body weight and height were measured using a balance beam scale. Height and weight were used to calculate Body mass index (BMI, kg/cm2). Waist circumference (WC, cm) was assessed as a surrogate marker of visceral obesity. Cardiovascular risk (CVR) was assessed using the scoring system of the Framingham Risk Score  ADDIN REFMGR.CITE (17, 18). Blood samples were used for biochemical measurements and for PBMCs isolation, and then stored at -80°C until employed for RNA extraction and purification. The study protocol was performed conform the declaration of Helsinki, approved by the Ethical Committee of the Azienda Ospedaliero-Universitaria Policlinico of Bari, Italy. All patients gave their informed consent for the use of clinical data and blood samples for scientific research purposes connected to this project.

Sample collection, PBMCs isolation, and flow cytometry
Fresh whole blood (18 mL) was collected by standardized venipuncture in EDTA anti-coagulant tubes (Vacuette®, Italy). PBMCs were isolated immediately, after collection of blood samples, using a standard, previously validated protocol  ADDIN REFMGR.CITE (6, 7, 19). Cells were applied on 15 mL of Ficoll (Ficoll-PaqueTM PLUS, Ge Healthcare, Orsay, France) and centrifuged for 30 min at 460 g, 18 °C with no brake. Mononuclear cells were obtained from the central white band of the gradient, exhaustively washed in Dulbecco’s phosphate-buffered saline (DPBS; Life Technologies, Waltham, MA, USA), and were stored at – 80°C until RNA extraction, or used for the isolation of cell subpopulations by flow cytometry. Fluorescence-Activated Cell Sorting of CD14+ cells (monocytes) and CD14- cells (mainly lymphocytes) was obtained by FACS Vantage flow cytometer (BD Bioscience, San Jose, CA, USA) using an anti-CD14 antibody (Anti-Human CD14; BD Bioscience; Cat No. 345785), and immediately used for RNA extraction.

Detailed experimental procedures (Cell cultures, RNA processing, RTqPCR and arrays, western blotting, miR transfection, luciferase assays and cholesterol efflux methods, statistical and bioinformatics analysis) are provided in the Supplementary Material.
 
Results
Clinical characterization of the study population
We recruited 33 control subjects (M:F=17:16) and 33 patients with MS (M:F=16:17). Features of the study population are shown in Table S1. When compared with healthy controls, patients with MS were characterized by increased body weight, BMI, WC, and blood pressure. Plasma biochemistry of MS patients showed an impaired glucose balance (increased glycaemia, insulinaemia, HbA1c, HOMA-IR), dyslipidemia (increased LDL-c and triglycerides, decreased HDL-c), increased markers of inflammation (C-reactive protein, CRP; erythrocyte sedimentation rate, ESR; and Fibrinogen), uric acid, and transaminases. CVR calculated with the Framingham Risk Score was significantly increased as well in patients with MS.

Mapping of genes expression in PBMCs of subjects with metabolic syndrome
We first defined the gene expression signature characterizing circulating PBMCs of MS patients. To this end, we investigated by whole-genome microarrays changes in PBMCs transcriptional profiles in a subgroup of 20 MS patients versus 20 control subjects having RNA relative quality index (RQI) greater than 8, and then confirmed the most important results by RTqPCR in the overall population (RNA RQI>7). At a log2 ratio cut-off value of 0.37 (i.e. 1.3 folds), 678 genes were differentially expressed in human PBMCs of MS subjects (FDR ≤ 0.01). Out of the 678 genes differentially expressed in human PBMCs of MS subjects, 380 genes resulted significantly up-regulated (p-value<0.05; fold induction > 1.3) in the MS group, while 298 genes resulted significantly down-regulated (p-value<0.05; fold reduction< 1.3). In order to investigate functional relationships in the set of differentially expressed genes, we used the IPA software to study the pattern of activation of networks and/or pathways modulated by MS in the PBMCs. We show genes clustered into biological networks in Figure 1 (up-regulated) and 2 (down-regulated), and single genes and pathway analysis in Table S2. The differential changes of the most intriguing hits were also measured by RTqPCR in the expanded validation cohort (Figure 3).
Different networks (i.e. hematological system development and function, immunological diseases, humoral immune responses, antigen presentation), and pathways (i.e. leukocyte extravasation signaling, NF-kB signaling and activation, chemokine signaling, hypoxia-inducible factor 1-alpha signaling) point to an over-activation of the immune system in MS, also featuring the up-regulation of toll-like receptor 5 [TLR5 plays a fundamental role in pathogen recognition and activation of nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) mediated immune responses; upregulation of TLR5 has been found by others in visceral adipose tissue of obese mice (20), but its role in insulin-resistance and MS remains controversial  ADDIN REFMGR.CITE (20, 21)], interleukin 32 [IL-32; a newly-discovered player in innate and adaptive immune response, which acts as a pro-inflammatory factor and may be implicated in the inflammatory cascade contributing to atherosclerosis  ADDIN REFMGR.CITE (22-24)], integrin alpha L [ITGAL; a subunit of the integrin lymphocyte function-associated antigen-1, LFA-1, that plays a central role in leukocyte intercellular adhesion toward interaction with intercellular adhesion molecules (ICAMs)  ADDIN REFMGR.CITE (25)], and of ICAM2 that function together also as co-stimulatory signaling in immune cells (26). We also found a suppression of different pathways involved in the regulation of immune response (glucocorticoid and estrogen receptors, interferon signaling, IL-4 signaling), featuring the suppression of conserved helix-loop-helix ubiquitous kinase (CHUK), a member of the serine/threonine protein kinase family, which plays a key role in the negative feedback of NF-κB canonical signaling to limit macrophage activation and inflammatory gene activation  ADDIN REFMGR.CITE (27, 28), and of the ligand-binding chain (alpha) of the interferon gamma receptor 1 (IFNGR1), which plays an important role in the protection, clearance and modulation of the immune response during infection  ADDIN REFMGR.CITE (29). Intriguingly in the overall population, ITGAL and ICAM2 mRNA abundance (RTqPCR) was positively correlated to BMI (p<0.01, r=0.3; p<0.01, r=0.5, respectively), and fibrinogen (p<0.05, r=0.3; p<0.05, r=0.3, respectively), while CHUCK was negatively correlated to ESR (p<0.05, r=-0.3), Figure S1.
One further important feature of the PBMCs signature in MS is represented by the high proliferative behavior, as shown by the enrichment of network and pathways involved in cell cycle, cancer and growth factor activity. These changes featured an up-regulation of the mitogen-activated protein 4 kinase 1 (MAP4K1), which is principally expressed in hematopoietic cells and is known to regulate stress responses, apoptosis and cell proliferation in cancer cells  ADDIN REFMGR.CITE (30), and of the mitogen-activated protein kinase 13 (MAPK13), a p38 MAP kinase activated by extracellular stimuli such as pro-inflammatory cytokines and cellular stress and that is involved in cell proliferation and differentiation  ADDIN REFMGR.CITE (31, 32). 
We also profiled the down-regulation of phosphatase and tensin homologue (PTEN), a well-established tumor-suppressor, which has been also found to be intimately connected to obesity and insulin signaling  ADDIN REFMGR.CITE (10, 33, 34). Intriguingly, levels of PTEN mRNA expression (RTqPCR) in the expanded population was negatively correlated with BMI (p<0.01, r=-0.4), and HOMA-IR (p<0.01, r=-0.3), Figure S1. The differential changes of IL-32, ICAM-2, ITGAL, MAP4K1, CHUK, IFNGR1, and PTEN were validated by RTqPCR in the expanded validation cohort (Figure 3). Moreover, we also confirmed the mRNA modulation of IL-32, ICAM2 and PTEN in the CD14+ and CD14- cell subpopulations (Figure 3).
Overall, these data depict an intriguing scenario where metabolism, inflammation, immunity and cell cycle are significantly modulated in circulating cells of MS patients well before the instauration of clinically-significant atherosclerosis, type 2 diabetes or cancer.

miRNAs expression chart of PBMCs in metabolic syndrome 
The main goal of our study was to define the miRNAs expression signature characterizing PBMCs in MS patients, and integrate these results with GE to find candidate mechanisms of post-transcriptional regulation of mRNA abundance, stability and translation. To this end, we investigated changes in PBMCs transcriptional profiles in 20 MS patients versus 20 control subjects by global miRNA expression profiling. We identified 688 miRNAs being expressed in the PBMCs of our cohort. After log2 transformation and filtering for a log2 ratio cut-off value of 0.37 (i.e. 1.3 folds), 84 annotated miRNAs were differentially expressed in human PBMCs of MS subjects (FDR ≤ 0.01). Of these 84 hits, 53 miRNA resulted significantly up-regulated in the MS group, while 31 miRNA resulted significantly down-regulated in the MS group (Table S3). We also used bioinformatics prediction tools of IPA and Target Scan to unravel mRNAs target of each miRNA that were also regulated in our dataset, thus providing a fine miR-mediated candidate “tuning” of the transcriptome of PBMCs underlying MS.
In the PBMCs of MS patients, we found modulation of miRNAs involved in the regulation of innate immune responses and adaptive immunity. Indeed, we observed the up-regulation of miR-324-3p that sustains chronic inflammation and tumorigenesis in the colon  ADDIN REFMGR.CITE (35), and of several miRNAs known to be targets of pro-inflammatory pathways and involved in negative feedback loops crucial for a tight regulation of inflammation such as miR-146a [a endotoxin-responsive miRNA abundantly expressed in myeloid cells monocytes/macrophages where it plays an anti-inflammatory role acting as negative regulator of IL-1/tumor necrosis factor signaling and NF-κB activation  ADDIN REFMGR.CITE (36-38)], miR-9-5p [a endotoxin-responsive miRNA acting as a feedback loop on NF-κB activity  ADDIN REFMGR.CITE (13, 14); miR-9 expression level has been also found to be higher in M1 compared with M2 macrophages, and has also been shown to inhibit the peroxisome proliferator-activated receptor delta, PPARδ  ADDIN REFMGR.CITE (15), which we have previously shown to be suppressed in the PBMCs of MS patients  ADDIN REFMGR.CITE (6)], and miR-223-3p [a downstream target of pro-inflammatory pathways  ADDIN REFMGR.CITE (39), shown to be involved in the modulation of NF-kB, IL-1β, CHUK (40), and macrophage polarization  ADDIN REFMGR.CITE (41-43)]. miR-223 is not only involved in the immune regulation but also in cholesterol homeostasis in hepatocytes where it limits HDL cholesterol uptake by directly repressing the scavenger repressor BI (SR-BI), and inhibits cholesterol biosynthesis via targeting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)  ADDIN REFMGR.CITE (12). Of interest, we also found the repression of miR-125b-1-3p [that has been shown to inhibited by lipopolysaccharide  ADDIN REFMGR.CITE (44); miR-125b inhibition leads to NF-κB pathway activation  ADDIN REFMGR.CITE (45)], and of both miR-126-3p and miR-126-5p [miR-126 is known to repress inflammatory factors such as chemokine (C-C motif) ligand 2 (CCL2)  ADDIN REFMGR.CITE (46) and to inhibit angiogenesis  ADDIN REFMGR.CITE (47), and has been also found reduced in the PBMC subset populations from diabetic patients  ADDIN REFMGR.CITE (47)]. 
These results show that the miRNome actively participates to the pro-inflammatory shift of the immune cells in MS, and that a better understanding of miRNA regulation and function could lead to the identification of candidate biomarkers of disease and putative targets for treatment of MS.

Dysregulation of miR-9/ABCA1 pair modulates cholesterol efflux in MS 
One of the components of MS definition is represented by a reduced level of HDL cholesterol and consequent RCT. Although monocytes per se have been proven to contribute only to small part of total RCT, circulating monocytes contribute to the enrichment of macrophages in different tissues, including AT and atherosclerotic plaques  ADDIN REFMGR.CITE (48-50). GE microarray analysis suggested a suppression of the ABCA1 in MS subjects that was confirmed by RTqPCR in our expanded validation cohort (Figure 4A), in the CD14+ and CD14– cells subsets (Figure 4B & C), and at protein level (PBMC) by western blot analysis conducted on a subgroup of these subjects (Figure 4D). ABCA1 plays a central role in the HDL cholesterol formation from pre-HDL since it functions as a cholesterol efflux pump in the cellular lipid removal pathway preventing atherosclerosis  ADDIN REFMGR.CITE (48, 49). It is thus not surprising to find ABCA1 transcript being positively correlated with HDL cholesterol (p<0.05, r=0.3) while being negatively correlated with BMI (p<0.01, r=-0.4), HOMA-IR (p<0.01, r=-0.4), and TG (p=0.01, r=-0.3). Details in Figure 4F-I. 
The canonical transcriptional regulation of ABCA1 expression involves the activation of liver X receptor/retinoid X receptor (LXR/RXR) heterodimer  ADDIN REFMGR.CITE (51), that we have previously shown to be unchanged in the PBMCs of patients with MS  ADDIN REFMGR.CITE (6). Nevertheless, a novel layer of cholesterol homeostasis regulation has been revealed by the ABCA1 mRNA susceptibility to posttranscriptional degradation of several miRNAs  ADDIN REFMGR.CITE (12). The miRNA target prediction tool of IPA (based on Target Scan dataset) predicted three of our differentially modulated miRNAs to be candidate modulators of ABCA1 (miR-9-5p, miR-128-3p, and miR-324-3p). We also found up-regulated miR-144, miR-26b-3p and miR-27a-5p that are already proven modulators of ABCA1  ADDIN REFMGR.CITE (12). We thus focused our attention on the new candidate ABCA1 modulators, and confirmed our array data by RTqPCR validation in the expanded cohort (33 healthy subjects and 33 MS patients). The up-regulation of the three miRNAs was confirmed in the overall PBMCs (Figure 5A and Figure S2A & I) but, while miR-9-5p (Figure 5B & C) was increased also in the CD14+/- cell sub-populations of MS subjects, miR-128-3p (Figure S2B & C) and miR-324-3p (Figure S2J & K) were unchanged in CD14+/- cells suggesting that the observed changes in the PBMC expression of these two miRNAs were thus most-likely the result in PBMC composition rather than of their intra-cellular modulation. Interestingly, miR-9-5p (Figure 5D) abundance in PBMC, but not miR-128-3p and miR-324-3p (Figure S2D & L), was negatively correlated to ABCA1 (p<0.05, r=-0.3); miR-9-5p expression levels were also negatively correlated to HDL levels (Figure 5E; p<0.05, r=-0.3) and positively correlated to BMI (Figure 5F; p=0.01, r=0.3), HOMA-IR (Figure 5G; p<0.01, r=0.3), and TG (Figure 5H; p<0.01; r=0.4). In line with these findings, the CE capacity of monocytes isolated from the PBMCs of patients with MS was reduced when compared to healthy controls (Figure 6A) and, as expected, CE was significantly and positively correlated to ABCA1 mRNA expression levels (Figure 6B; p<0.01; r=0.8) and negatively correlated to miR-9-5p expression levels (Figure 6C; p<0.01; r=-0.7).
To further prove the direct role of miR-9-5p in the modulation on ABCA1 expression and function (cholesterol efflux), we differentiated human THP-1 cell line into macrophages and ectopically modulated (gain and loss of function) miR-9-5p. Here we show that over-expression of miR-9-5p is associated to a reduction of ABCA1 mRNA and protein level, while miR-9-5p silencing leads to increased ABCA1 transcript and protein abundance [Figure 7; additional targets of miR-9-5p suggested by IPA miRNA target prediction tool - FURIN, phosphodiesterase 3B (PDE3B), SERPINE1 mRNA binding protein 1 (SERBP1), and zinc finger protein 24 (ZNF24) - are shown in Figure S3]. The reporter assay in HEK-293 (using ABCA1 miRNA 3’UTR target sequence) confirms ABCA1 as a target of miR-9-5p (Figure 7J). We then assessed the functional consequences of miR-9-5p over-expression and inhibition on the cholesterol efflux capacity of THP1-derived macrophages. Remarkably, miR-9-5p over-expression and inhibition significantly attenuates and increases the fluorescent cholesterol efflux capacity, respectively, when compared to control miRNAs (Figure 7K). These results show that miR-9-5p manipulation significantly alters macrophage ABCA1 expression hereby leading to a modulation of cholesterol efflux from macrophages, which is a functional measure of HDL cholesterol and a critical step in RCT  ADDIN REFMGR.CITE (50).

Discussion
The cross-talk between immune and metabolic cells in chronic state of low-grade inflammation plays a central role in the disturbance of metabolic homeostasis, and in the development of cardiovascular complications  ADDIN REFMGR.CITE (52). In this regard, PBMCs are crucial player in orchestrating inflammatory response, lipid homeostasis, and in driving atherosclerotic lesion formation (4). In this study, by using a genome-wide screening, the specific gene and miRNAs expression signature in circulating PBMCs of MS patients without clinically-significant organ damage. MS is a precursor state of coronary artery disease and type 2 diabetes, and which are involved in the regulation of the pro-inflammatory response activation and propagation [e.g. CHUK  ADDIN REFMGR.CITE (27, 28, 53), IFNGR1  ADDIN REFMGR.CITE (29), miR-9-5p  ADDIN REFMGR.CITE (13, 14), miR-223-5p  ADDIN REFMGR.CITE (40-43), and miR-126  ADDIN REFMGR.CITE (46)], the cross talk between immune cells [e.g. IL-32  ADDIN REFMGR.CITE (22-24), miR-125b-1-3p  ADDIN REFMGR.CITE (45), miR-324-3p  ADDIN REFMGR.CITE (35)], leukocyte intercellular adhesion [e.g. ITGAL and ICAM2  ADDIN REFMGR.CITE (25, 26)], cell proliferation [e.g. MAP4K1  ADDIN REFMGR.CITE (30-32)], and lipid/glucose metabolism [i.e. PTEN  ADDIN REFMGR.CITE (10, 33, 34), miR-26b-3p, miR-27a-5p  ADDIN REFMGR.CITE (12), miR-128-3p, miR-144  ADDIN REFMGR.CITE (12), miR-223-5p  ADDIN REFMGR.CITE (12)]. 
In order to identify novel link between inflammation and HDL cholesterol metabolism, we first profiled the suppression of ABCA1 that promotes cholesterol efflux from macrophages into relatively lipid-poor pre-βHDL particles thereby initiating the process of reverse cholesterol transport (RCT)  ADDIN REFMGR.CITE (48-50). RCT is a critical pathway to prevent cholesterol accumulation into the vessels wall, thus preventing atherosclerosis (49). While the classical transcriptional regulation of ABCA1 expression through the LXR/RXR system is well established  ADDIN REFMGR.CITE (51), mounting evidence suggests that another layer of cholesterol efflux regulation might be achieved by ABCA1 mRNA post-transcriptional inhibition mediated by several miRNAs (e.g. miR-33a/b, miR-26, miR-27a/b miR-128-1, miR-144, miR-148a, miR-223) that can be modulated in disease  ADDIN REFMGR.CITE (12). Our results suggest that the pro-inflammatory changes characterizing inflammatory cells in MS are associated to a suppression of ABCA1, and that ABCA1 in PBMCs of MS patients correlates with HDL cholesterol and cholesterol efflux. To provide evidence of MS-driven changes in miRNAs possibly involved in RCT, we identified the set of PBMCs-specific miRNAs dysregulated in MS and then we explored their possible role in mediating ABCA1 expression. IPA identified miR-9-5p, miR-128-3p, and miR-324-3p, all up-regulated in MS, as candidate modulators of ABCA1 [miR-128-3p has been also experimentally confirmed in mouse macrophages  ADDIN REFMGR.CITE (12)]. Of these three candidates, only miR-9-5p dysregulation was also confirmed in the CD14+ cells (mainly monocytes), that are the most likely to contribute to the atherosclerosis. Intriguingly, miR-9-5p was also found to be negatively correlated to ABCA1, HDL cholesterol and cholesterol efflux. On the basis of these findings, we then decided to explore the role of miR-9 in modulating ABCA1 through genetic manipulation. Ectopic modulation of miR-9-5p by using gain and loss of function approaches in the human monocyte/macrophage THP-1 cell line confirmed miR-9-mediated ABCA1 modulation leading to the suppression of cholesterol efflux. 
In conclusion, our findings suggest that MS is associated to the dysregulation of different miRNA involved in the cholesterol efflux regulation, and expanded the existing knowledge with a new actor. Indeed, MS-associated inflammation leads to the over-expression of miR-9-5p  ADDIN REFMGR.CITE (13) that negatively influences ABCA1 expression, cholesterol efflux, and RCT. miR-9-5p is a known target of inflammatory pathways  ADDIN REFMGR.CITE (13-15), also involved in the modulation of the expression of the fatty acid sensor PPAR in monocytes  ADDIN REFMGR.CITE (15), that we previously described as suppressed in the PBMCs of MS patients  ADDIN REFMGR.CITE (6). miR-9-5p has been also found upregulated in the liver of biopsy-proven non-alcoholic fatty liver disease patients with low HDL  ADDIN REFMGR.CITE (54) [liver ABCA1 correlates with HDL levels in obese patients with non-alcoholic steatohepatitis  ADDIN REFMGR.CITE (55)], where it appears also to act as a master regulator of hepatic metabolism  ADDIN REFMGR.CITE (54). Our results thus suggest a possible systemic role of this miRNA in the regulation of lipid and cholesterol metabolism that merits further investigation. Dysregulation of the miR-9-5p in MS could be a new pivotal pathophysiologic mechanism leading to metabolic unbalances, ABCA1 dysfunction and reduced HDL levels, all features that characterize MS pathophysiology. Moreover, the modulation of these processes could constitute a putative strategy to treat metabolic disease and reduce cardio-metabolic risk.
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Figure 1. Matrix of up-regulated genes in MS patients (vs. healthy subjects). 
Genes up-regulated in MS were profiled using microarrays and clustered (using IPA) in large networks displaying a coordinate biological function. The data are shown in a heatmap with a matrix format; each single row represents the expression of one gene in a single patient (defined by columns). The difference between two groups was assessed with Mann-Whitney U test (20 healthy subjects vs. 20 MS patients) on the Log2 normalized data. The raw p values were then adjusted by the Benjamini-Hochberg procedure to control the “false discoveries rate” (FDR). The expression level of each gene is represented by a color (red: expression greater than the mean; black: expression equal to the mean; green: expression smaller than the mean). Lateral bar represents fold-changes among groups.

Figure 2. Matrix of down-regulated genes in MS patients (vs. healthy subjects). 
Genes down-regulated in MS patients were profiled using microarrays and clustered (using IPA) in large networks displaying a coordinate biological function. The data are shown in a heatmap with a matrix format; each single row represents the expression of one gene in a single patient (column). The difference between two groups was assessed with Mann-Whitney U test (20 healthy subjects vs. 20 MS patients) on the Log2 normalized data. The raw p values were then adjusted by the Benjamini-Hochberg procedure to control the “false discoveries rate” (FDR). The expression level of each gene is represented by a color (red: expression greater than the mean; black: expression equal to the mean; green: expression smaller than the mean). Lateral bar represents fold-changes among groups.

Figure 3. mRNA expression profiles of IL-32, ICAM2, ITGAL, MAP4K1, CHUK, IFNGR1, and PTEN. 
mRNA expression levels of IL-32 were increased in the (A) PBMCs (33 patients/group), (B) CD14+ cells (22 patients/group), and (C) CD14- cells of subjects with MS (22 patients/group). mRNA abundance of (D) ICAM2, (E) ITGAL, and (F) MAP4K1 was also confirmed to be up-regulated in the PBMCs of MS patients. mRNA expression levels of PTEN were decreased in the (I) PBMCs, (J) CD14+ cells, and (K) CD14- cells of subjects with MS. We also confirmed the down-regulation of (G) CHUK, and (H) IFNGR1 in the PBMCs of MS patients. Data were normalized on “Cyclophilin A” mRNA levels, presented as fold change, and plotted as mean ± SD (* = p≤0.05). Difference between two groups was assessed with Mann-Whitney U test; p-values ≤ 0.05 were considered statistically significant. 

Figure 4. mRNA and protein expression profiles of ABCA1, and its correlations with clinical variables. 
mRNA expression levels of ABCA1 were increased in the (A) PBMCs (33 patients/group), (B) CD14+ cells (22 patients/group) and (C) CD14- cells of subjects with MS (22 patients/group). The data were normalized on “Cyclophilin A” mRNA levels, presented as fold change, and plotted as means ± SD (* = p≤0.05). (D and E) Quantification of ABCA1 protein, normalized to β-Actin content, revealed a significant reduction in ABCA1 levels in the PBMCs of MS patients (6 healthy controls vs. 6 MS patients). In the overall population, ABCA1 mRNA level was significantly and negatively (p<0.01, r=-0.4) correlated to (F) BMI, (G) HOMA-IR, and (H) TG (p=0.01, r=-0.3), while was significantly and positively (p<0.05, r=0.3) correlated to (I) HDL-c. The difference between two groups was assessed with Mann-Whitney U test. The correlation between variables was assessed with Pearson’s correlation coefficient. p-values ≤ 0.05 were considered statistically significant. Legend: (white) control subjects; (black) MS patients.
Figure 5. Expression profiles of miR-9-5p, and its correlations with clinical variables. Expression levels of miR-9-5p were increased in the (A) PBMCs (33 patients/group), (B) CD14+ cells (22 patients/group) and (C) CD14- cells of subjects with MS (22 patients/group). The data were normalized on miR-16 expression levels, presented as fold change, and plotted as means ± SD (* = p≤0.05). In the overall population, miR-9-5p expression levels were significantly and negatively correlated to (D) ABCA1 (p<0.05, r=-0.3), and (E) HDL-c (p=0.05, r=-0.3), while was significantly and positively correlated to (F) BMI (p=0.01, r=0.3), (G) HOMA-IR (p<0.01, r=0.3), and (H) TG (p<0.01; r=0.4). The difference between two groups was assessed with Mann-Whitney U test. The correlation between continuous variables was assessed with Pearson’s correlation coefficient. p-values ≤ 0.05 were considered statistically significant. Legend: (white) control subjects; (black) MS patients.

Figure 6. The cholesterol efflux is reduced in monocytes of MS patients and correlates with ABCA1 and miR-9 abundance. 
(A) The cholesterol efflux of monocytes cells derived from PBMCs of patients with MS was reduced when compared to healthy controls (6 patients/group), positively correlated to ABCA1 mRNA expression levels (B; p<0.01; r=0.8), and negatively correlated to miR-9-5p expression levels (C; p<0.01; r=-0.7). The difference between two groups was assessed with Mann-Whitney U test. The correlation between continuous variables was assessed with Pearson’s correlation coefficient. p-values ≤ 0.05 were considered statistically significant. Legend: (white) control subjects; (black) MS patients.

Figure 7. Modulation of ABCA1 and cholesterol efflux by miR-9-5p mimic and inhibitor.
The transfection of mir-9-5p mimic (40 nM; 24h incubation) induced increased miR-9-5p expression levels (A), suppressed ABCA1 mRNA (B) and protein (C & D). The transfection of miR-9-5p inhibitor (100 nM; 24h incubation) significantly decreased miR-9-5p level (E), leading to ABCA1 (F) mRNA and protein (G & H) overexpression compared with control vector-treated THP-1-derived macrophages. (J) In HEK-293 cells, miR-103 mimic (black) and inhibitor (grey) were transfected together with a ABCA1 3′UTR reporter construct carrying miR-9-5p binding sequence (I; “CCAAAG”); changes in luciferase activity confirm the ability of miR-9-5p to modulate ABCA1. (K) miR-9-5p mediated changes in cholesterol efflux capacity were also investigated in THP-1 derived macrophages confirming the ability of miR-9 to modulate cholesterol efflux. All the experiments were carried transfecting non-targeting control mimic (control gain, CG) or miR-9-5p mimic (Gain), and inhibitor negative control (control loss, CL) or miR-9-5p inhibitor (Loss, L). Data are presented as mean ± SD (n: 4/treatment; * = p≤0.05). The difference between two groups was assessed with Mann-Whitney U test; p-values ≤ 0.05 were considered statistically significant.
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